If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Lilly has not identified any safety concerns, including adverse reactions or side effects, associated with temporary interruption or withdrawal of Forteo® (teriparatide [rDNA origin] injection) therapy during our clinical studies or follow-up analyses (Neer, 2001; Orwoll, 2003; Lindsay, 2004; Saag, 2007; Saag 2009; Silverman, 2013).
It is not known how stopping and starting teriparatide effects how it works as teriparatide was studied as a once daily injection without interruptions for 24 months (Forteo Package Insert, 2012).
Inform your physician if you had to stop teriparatide for any period of time.
Enclosed Prescribing Information
The published references below are available upon request by contacting 1-800-LillyRx.
FORTEO® [Package Insert]. Indianapolis, IN: Eli Lilly and Company; 2012.
Saag KG, Zanchetta JR, Devogelaer J-P, et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum. 2009;60(11):3346-3355.
Silverman S, Miller P, Sebba A, et al. The Direct Assessment of Nonvertebral Fractures in Community Experience (DANCE) study: 2-year nonvertebral fragility fracture results. Osteoporosis Int. 2013;24(8):2309-2317.
Date of Last Review: February 12, 2017